Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects
Author:
Affiliation:
1. Clinical Pharmacology and Pharmacometrics; AbbVie; North Chicago IL USA
2. Data and Statistical Science; AbbVie; North Chicago IL USA
3. Infectious Diseases; AbbVie; North Chicago IL USA
4. Medical Affairs; AbbVie; North Chicago IL USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. Polaris Observatory-global prevalence of hepatitis C;Blach S;Hepatology,2016
2. Ng T Reisch T Middleton T McDaniel K ABT-493, a potent HCV NS3/4A Ppotease inhibitor with broad genotype coverage
3. Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study;Lin;J Pharm Sci,2017
4. Ng T KP Kati W Reisch T ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high geneti c barrier to resistance
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents;Clinical Pharmacokinetics;2023-09-20
2. Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co‐formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults;Clinical Pharmacology in Drug Development;2023-09-04
3. Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment;Scientific Reports;2022-05-12
4. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection;Journal of Clinical and Translational Hepatology;2021-01-18
5. Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2);The Lancet Gastroenterology & Hepatology;2020-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3